Genmab And AbbVie Announced FDA Granted Priority Review For The Supplemental Biologics License Application For Epcoritamab-bysp For Relapsed/Refractory Follicular Lymphoma After Two Or More Lines Of Systemic Therapy
Author: Benzinga Newsdesk | February 27, 2024 08:47am